TNK2 and breast cancer: Initially, upon treatment of MDA-MB-231 breast cancer cells with siRNA directed against TNK2, we observed morphological changes by 48 hours post transfection – indicative of cytoskeletal remodelling – that were characterised by an increasingly elongated stellate appearance with a distinct absence of protrusions at the membrane edges (Figure 1a).